TACE联合经皮无水乙醇注射在原发性肝癌治疗中的价值  

Transcatheter hepatic arterial chemoembolization combined percutaneous ethanol injection in treating primary hepatic carcinoma

作　　者：郭晓华[1] 何建荣[1] 金红来[1] 林开勤[1] 胡晓刚[1] 

机构地区：[1]浙江省金华市中心医院介入治疗室,浙江金华321000

出　　处：《医学影像学杂志》2009年第5期555-557,共3页Journal of Medical Imaging

摘　　要：目的:评价肝动脉灌注化疗栓塞(TACE)、经皮无水乙醇注射联合治疗原发性肝癌的价值。方法:应用TACE单独治疗原发性肝癌64例,TACE与PEI联合治疗原发性肝癌21例。术后对比12个月,18个月,24个月生存期,评价TACE与PEI联合治疗的价值。结果:TACE+PEI组肿瘤缩小有效率为85.71%,TACE组肿瘤缩小有效率68.75%。TACE+PEI组1、2、3年生存率分别为97.2%、72.1%、39.6%。TACE组患者1、2、3年生存率分别为83.6%、34.3%、16.2%。结论:TACE联合PEI可以提高原发性肝癌的疗效。Objective：To evaluate clinical efficacy of the transcatheter hepatic arterial chemoenbolization （TACE）combined pereutaneous ethanol injection（PEI）in treating primary hepatic carcinoma. Methods： 85 cases with primary hepatic carcinoma were divided into TACE ＋ PEI group and TACE group. 21 cases underwent TACE combined PEI treatment, 64 cases underwent TACE treatment. Results： The effective rate of TACE＋ PEI group is 85.71%, the one of TACE group is 68.75%. The lyear, 2 year, 3 year survival rates of the TACE ＋ PH group and TACE group were 97.2 %, 72. 1%, 39.6 % and 83.6 %, 34.3 %, 16.2 % respectively. Conclusion： TACE combined PEI is a better treatment of primary hepatic carcinoma.

关 键 词：原发性肝癌 肝动脉关注化疗栓塞 经皮注射无水乙醇 

分 类 号：R735[医药卫生—肿瘤] R815[医药卫生—临床医学]